期刊文献+

36例骨髓增生异常综合征患者铁过载状况调查

Survey of the iron overload status in 36 patients with myelodysplastic syndrome
原文传递
导出
摘要 目的:调查36例骨髓增生异常综合征(MDS)患者的铁过载发生率及铁过载严重程度。方法:收集MDS患者36例,采用电化学发光法测定其血清铁蛋白(SF)。结果:36例MDS患者的SF为851.42(360.75~7 885.62)ng/ml,其中16例(44.4%)SF>1 000ng/ml。14例有输血史,SF为887.14(360.75~7 885.62)ng/ml,其中7例(50.0%)SF>1 000ng/ml;22例无输血史,SF为851.42(459.87~5 277.71)ng/ml,其中9例(40.9%)SF>1 000ng/ml。SF<1 000ng/ml者(20例)与SF>1 000ng/ml者(16例)的输血量分别为4U和36U,差异有统计学意义(P=0.024)。SF水平与输血总量呈正相关(P=0.000)。不同年龄段间SF值差异有统计学意义(P=0.022)。结论:本组MDS患者中16例(44.4%)出现铁过载。铁过载的发生与输血有关,但无输血史的患者中也有9例(40.9%)出现铁过载。 Objective:To investigate the incidence and severity of iron overload in 36 patients with myelodysplastic syndrome(MDS). Method:The serum ferritin(SF) was measured by electrochemiluminescence immunoassay(ECLIA) in 36 patients with MDS. Result:In the 36 patients with MDS,the SF value was 851.42(form 360.75 to 7 885.62)ng/ml,16 patients(44.4%) with SF1 000 ng/ml.Fourteen patients had a history of blood transfusion,the SF value was 887.14(from 360.75 to 7 885.62)ng/ml,7 cases(50.0%) with SF1 000 ng/ml.Twenty-two patients without history of blood transfusion,the SF value was 851.42(from 459.87 to 5 277.71)ng/ml,9 cases(40.9%) with SF1 000 ng/ml.The amount of blood transfusion in patients with SF1 000 ng/ml and SF1 000 ng/ml were 4 U and 36 U(P=0.024).SF was positively correlated with the total blood transfusion(P=0.000).There were significant differences in the SF values among difference ages(P=0.022). Conclusion:In this study,16 patients(44.4%) are iron overloaded.The occurrence of iron overload is correlated with transfusion,but 9 cases(40.9%) in the patients without history of blood transfusion also occurs iron overload.
出处 《临床血液学杂志》 CAS 2013年第4期455-457,461,共4页 Journal of Clinical Hematology
关键词 骨髓增生异常综合征 铁过载 myelodysplastic syndrome iron overload
  • 引文网络
  • 相关文献

参考文献13

  • 1铁过载诊断与治疗的中国专家共识[J].中华血液学杂志,2011,32(8):572-574. 被引量:112
  • 2JABBOUR E, KANTARJIAN H M, KOLLER C, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes [J]. Cancer, 2008,112 : 1089- 1095.
  • 3SUZUKI T, TOMONAGA M, MIYAZAKI Y, et al. Japanese epidemiological survey with consensus state- ment on Japanese guidelines for treatment of iron o- verload in bone marrow failure syndromes[J]. Int J Hematol, 2008,88 : 30 - 35.
  • 4GREENBERG P L, ATTAR E, BENNETT J M, et al. NCCN Clinical Practice Guidelines in Oncology: myetodysplastic syndromes[J]. J Natl Compr Canc Netw,2011,9:30-56.
  • 5ROSE C, BRECHIGNAC S, VASSILIEF D, et al. Does iron chelation therapy improve survival in regu- larly transfused lower risk MDS patients? A multi- center study by the GFM[J]. Leuk Res, 2010, 34: 864-870.
  • 6LEITCH H A,CHAN C,LEGER C S,et al. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non RARS diagno- sis[J]. Leuk Res,2012,36 : 1380-1386.
  • 7NEUKIRCHEN J, FOX F, KONDGEN A, et al. Im proved survival in MDS patients receiving iron chela- tion therapy - a matched pair analysis of 188 patients from the Dtisseldorf MDS registry [J]. Leuk Res, 2012,36 : 1067 - 1070.
  • 8ALESSANDRINO E P,DELLA PORTA M G,BACI- GALUPO A, et al. Prognostic impact of pre-trans- plantation transfusion history and secondary iron o-verload in patients with myelodysplastic syndrome un dergoing allogeneic stem cell transplantation: a GIT MO study[J]. Haematologiea, 2010,95 : 476 - 484.
  • 9KATAOKA K, NANNYA Y, HANGAISHI A, et al. Influence of pretransplantation serum ferritin on non relapse mortality after myeloablative and nonmyeloab lative allogeneic hematopoietic stem cell transplanta tion[J] Biol Blood Marrow Transplant, 2009, 15 195-204.
  • 10ARMAND P,SAINVIL M M,KIM H T,et al. Does i ron overload really matter in stem cell transplanta tion? [J]AmJ Hematology,2012,87:569-572.

二级参考文献18

  • 1Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93:741-752.
  • 2Bennett JM, MDS Foundation' s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodys- plastic syndromes. Am J Hematol, 2008, 83:858-861.
  • 3Wells RA, Leber B, Buckstein R, et al. Iron overload in myelo- dysplastic syndromes:a Canadian consensus guideline. Leuk IRes, 2008, 32 : 1338-1353.
  • 4Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med, 2009, 60:25-38.
  • 5Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diag- nosis and management of aplastic anaemia. Br J Haematol, 2009, 147 :43-70.
  • 6Lipinski P, Starzynski RR, Stys A, et al. Iron homeostasis, a de- fense mechanism in oxidative stress. Postepy Biochem,2010,56: 305-316.
  • 7Ghoti H, Amer H,Winder A, et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol, 2007,79: 463- 467.
  • 8Fibach E, Rachmilewitz EA. The role of antioxidants and iron che- lators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci, 2010, 1202:10 - 16.
  • 9Prus E, Fibach E. Effect of iron chelators on labile iron and oxida- tive status of thalassaemie erythroid cells. Acta Haematol,2010, 123 : 14 -20.
  • 10Messner DJ, Kowdley KV. Neoplastic transformation of rat liver ep- ithelial cells is enhanced by non-transferrin-bound iron. BMC Gas- troenterol,2008,8 : 2.

共引文献119

;
使用帮助 返回顶部